<?xml version='1.0' encoding='utf-8'?>
<document id="31724042"><sentence text="Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin."><entity charOffset="48-59" id="DDI-PubMed.31724042.s1.e0" text="Cefiderocol" /><entity charOffset="81-94" id="DDI-PubMed.31724042.s1.e1" text="Cephalosporin" /><pair ddi="false" e1="DDI-PubMed.31724042.s1.e0" e2="DDI-PubMed.31724042.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31724042.s1.e0" e2="DDI-PubMed.31724042.s1.e1" /></sentence><sentence text="Cefiderocol, a novel parenteral siderophore cephalosporin, exhibits potent in vitro activity and in vivo efficacy against most gram-negative bacteria, including carbapenem-resistant strains of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia"><entity charOffset="0-11" id="DDI-PubMed.31724042.s2.e0" text="Cefiderocol" /><entity charOffset="44-57" id="DDI-PubMed.31724042.s2.e1" text="cephalosporin" /><entity charOffset="161-171" id="DDI-PubMed.31724042.s2.e2" text="carbapenem" /><pair ddi="false" e1="DDI-PubMed.31724042.s2.e0" e2="DDI-PubMed.31724042.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31724042.s2.e0" e2="DDI-PubMed.31724042.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31724042.s2.e0" e2="DDI-PubMed.31724042.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31724042.s2.e1" e2="DDI-PubMed.31724042.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31724042.s2.e1" e2="DDI-PubMed.31724042.s2.e2" /></sentence><sentence text=" In phase 1 studies, cefiderocol demonstrated linear pharmacokinetics, primarily urinary excretion, an elimination half-life of 2-3 hours, and a protein binding of 58% in human plasma"><entity charOffset="21-32" id="DDI-PubMed.31724042.s3.e0" text="cefiderocol" /></sentence><sentence text=" Cefiderocol is a time-dependent cephalosporin; the probability of a target attainment at ≥75% of the dosing interval during which the free drug concentration exceeds the minimum inhibitory concentration (ƒT/MIC) for bacterial strains with an MIC of ≤4 μg/mL is likely to be achieved at the therapeutic dose of 2 g over 3-hour infusion every 8 hours in most patients"><entity charOffset="1-12" id="DDI-PubMed.31724042.s4.e0" text="Cefiderocol" /><entity charOffset="33-46" id="DDI-PubMed.31724042.s4.e1" text="cephalosporin" /><pair ddi="false" e1="DDI-PubMed.31724042.s4.e0" e2="DDI-PubMed.31724042.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31724042.s4.e0" e2="DDI-PubMed.31724042.s4.e1" /></sentence><sentence text=" As expected, renal function markers were the most influential covariates for the pharmacokinetics of cefiderocol for patients with renal impairment or augmented renal clearance (ARC)"><entity charOffset="102-113" id="DDI-PubMed.31724042.s5.e0" text="cefiderocol" /></sentence><sentence text=" Dose adjustment is recommended for patients with impaired renal function, and additionally, in ARC patients with creatinine clearance &gt;120 mL/minute, a more frequent dosing regimen (ie, 2 g every 6 hours) was predicted to achieve the target fT &gt; MIC"><entity charOffset="114-124" id="DDI-PubMed.31724042.s6.e0" text="creatinine" /></sentence><sentence text=" The single and multiple doses of cefiderocol tested were well tolerated in both healthy subjects and those with renal impairment"><entity charOffset="34-45" id="DDI-PubMed.31724042.s7.e0" text="cefiderocol" /></sentence><sentence text=" Furthermore, neither QT interval prolongation nor drug-drug interaction via organic anion transporters was demonstrated in healthy subjects" /><sentence text=" Cefiderocol is being investigated in phase 3 clinical studies for the treatment of infections caused by carbapenem-resistant bacteria"><entity charOffset="1-12" id="DDI-PubMed.31724042.s9.e0" text="Cefiderocol" /><entity charOffset="105-115" id="DDI-PubMed.31724042.s9.e1" text="carbapenem" /><pair ddi="false" e1="DDI-PubMed.31724042.s9.e0" e2="DDI-PubMed.31724042.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31724042.s9.e0" e2="DDI-PubMed.31724042.s9.e1" /></sentence><sentence text="" /></document>